Oppenheimer Upgrades Syneron Medical (ELOS) to Outperform
More News related to ELOS
- Syneron Medical (ELOS) Announces Expanded FDA Clearance for eMatrix
- Syneron Receives FDA Clearance for Expanded Indications of eMatrix(TM) Sublative Rejuvenation System
- Syneron Medical (ELOS) Misses the Street's Q4 Views
- Syneron Reports Fourth Quarter and Full Year 2009 Results
- Trading Radar for 02/11: PepsiCo (PEP), Viacom (VIA), Realty Income (O), Philip Morris Int. (PM), McAfee (MFE) Report
More News related to Upgrades
- Tudor Pickering Upgrades Energen (EGN) to Accumulate
- Macquarie Upgrades Penn West Energy Trust (PWE) to Outperform
- Oppenheimer Raises Boeing (BA) Two-Notches to Outperform; Downgrades Lockheed (LMT) to Perform
- Dick Bove Officially Moves to 'Buy' Rating On Citigroup (C)
- Cowen & Co Upgrades Boeing (BA) to Outperform
Oppenheimer upgrades Syneron Medical (Nasdaq: ELOS) from Market Perform to Outperform. Price target $16.
To see more analyst ratings on ELOS Click Here.
Syneron Medical Ltd. designs, develops, and markets aesthetic medical products.
Related Categories
UpgradesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
